Yale’s Dean of Public Health: Yale did not lose money due to Stavudine patent concession

“Most significantly for our purposes, the proportion of revenue that a university would obtain from developing countries, even on a blockbuster drug, will be vanishingly small–only a few percent of those few percent of total revenues that PhRMA companies make in LMI countries. Yale reported no lost revenue as a result of the stavudine patent concession in South Africa, and Yale’s Dean of Public Health Michael Merson stated that “[t]his change was made at Yale without any negative consequencesto the University-financial or otherwise.’

Link to source

Pages 1088-1089, Berkley Technology Law Journal, 2005


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s